Berlin, Germany, 26 February 2026. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today announced that it has entered a partnership with Molecular Partners AG to enable the development and future manufacturing of Molecular Partners’ radiolabeled therapeutics (Radio-DARPins) based on its proprietary Designed Ankyrin Repeat Protein (DARPin) technology platform.

Under the agreement, Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with Actinium-225 and Lutetium-177 payloads which show potential in the treatment of various cancers. The collaboration will leverage Eckert & Ziegler’s state-of-the-art laboratories, including the newly established development laboratory in Berlin. Thanks to its carefully selected and matched technical equipment, the facility offers ideal conditions for the advancement of radiopharmaceuticals based on alpha emitters.

DARPin molecules are a novel class of custom-built proteins. Their structure and favorable pharmacokinetic properties make them an attractive vector for the development of targeted radiopharmaceuticals, with the potential to address significant unmet medical needs.

“Supporting highly innovative companies such as Molecular Partners in developing their promising technology platforms is a key objective of our group,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Bringing together our expertise in isotopes, radiochemistry and development infrastructure with our partners’ innovations will enable patients worldwide to benefit from new treatments in the future.”

The collaboration further strengthens Eckert & Ziegler’s position as a preferred partner for companies developing innovative radiopharmaceutical platforms and underscores its role in supporting the growing radiopharmaceutical ecosystem from early development through clinical supply to commercial phases.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Molecular Partners
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35